Nicotinamide Testing Explained

What Does "Nicotinamide Testing" Mean in a Laboratory?

Nicotinamide (niacinamide, CAS 98-92-0) is the amide form of vitamin B3 — water-soluble, the precursor of the coenzymes NAD⁺ and NADP, and the same vitamin activity as niacin (nicotinic acid) but without the flushing side effect. It is added as a nutritional fortificant to infant formula and foods, used as a feed additive, formulated as a drug-substance vitamin, and increasingly used as a cosmetic active (skin-lightening, barrier repair). "Nicotinamide testing" in a laboratory is therefore not one assay but three distinct services answering different questions on different matrices: food / supplement / feed content assay (is the labelled amount correct?), clinical nutritional-status testing (is the patient deficient or toxic?), and cosmetic active-ingredient assay (is the cream at its declared %?). It must first be distinguished from nicotinamide mononucleotide (NMN) — an NAD⁺-precursor supplement that contains the nicotinamide moiety but is a different, larger molecule; the much-cited NMN supplement-quality studies are about NMN, not nicotinamide, and do not transfer.

Why Three Services — and Why Confusing Them Produces Wrong Reports

The methods look related (most end in HPLC or LC-MS/MS), but the sample preparation, the calibration, the detection limit and the acceptance criterion are matrix-specific. A food method (mg/g) is not a clinical method (ng/mL); a feed method (GB 7301) is not a cosmetic method. A test report must name the matrix and the standard.

How Is Food / Supplement / Feed Content Assay Performed?

For product release and regulatory compliance, nicotinamide is quantified in foods, supplements and feed against the declared content. The Chinese framework:

• Method standard — GB 5009.89-2023 (食品安全国家标准 食品中烟酸和烟酰胺的测定) provides the HPLC method for both nicotinic acid and nicotinamide in food matrices; older microbiological methods coexist for total-vitamin-B3 activity.
• Product / additive standards — GB 14753 (食品添加剂 维生素, including nicotinamide) for the additive grade; GB 14880 (食品营养强化剂使用标准) for the permitted use range and limits in fortified foods (infant formula, milk powder, health foods); GB 7301-2017 (饲料添加剂 烟酰胺, mandatory national standard) for the feed-additive grade; GB 15570 (食品添加剂 烟酸) for the nicotinic-acid additive.
• Method — typically HPLC or UPLC (C18 column, aqueous/organic mobile phase, UV or DAD detection) for mg/g-level content; LC-MS/MS for trace/complex matrices (infant formula, health foods) and for simultaneous nicotinamide + B6 vitamer quantification; microbiological / ELISA kit methods for high-throughput total-B3 screening.

The acceptance question is "does the measured content match the label within tolerance" — and the well-documented problem in the supplement industry is that it often does not: published surveys of NMN supplements found deviations from −100 % (no active detected) to +28.6 %. Nicotinamide supplements show the same pattern, which is why third-party content assay exists.

How Is Clinical Nutritional-Status Testing Performed?

For a patient, nicotinamide (and its acid form niacin) is measured to assess vitamin B3 status — but blood is the least reliable matrix, because plasma niacin/nicotinamide spikes 2 h after any intake and drops again. The clinically useful tests are:

• Plasma / serum LC-MS/MS (e.g. Mayo Clinic "Vitamin B3 and Metabolites") — quantifies nicotinic acid, nicotinamide and nicotinuric acid; useful mainly for toxicity monitoring of high-dose niacin therapy (cholesterol management), not for routine status. Typical ranges: nicotinamide 5–48 ng/mL; therapeutic can exceed 1000 ng/mL.
• Urinary metabolites (the gold standard for status) — N¹-methylnicotinamide (NMN) and 2-pyridone (2-Pyr), measured in 24-h urine (or spot with creatinine correction). Combined excretion: > 17.5 µmol/day adequate; 5.8–17.5 low; < 5.8 deficient. These reflect body stores over time, not a transient spike.
• Hair analysis — LC-MS/MS can detect and quantify nicotinamide in human hair (pg/mg range), offering a long-term, non-invasive complement to blood and urine.

The decision sequence is therefore: blood for toxicity monitoring of therapy; urine for deficiency/status assessment; and increasingly intracellular NAD⁺ measurement (the functional endpoint) rather than isolated precursor levels, because the goal of supplementation is cellular NAD⁺, not circulating nicotinamide per se.

How Is Cosmetic / Topical Nicotinamide Assayed?

Nicotinamide is one of the most widely used cosmetic actives — typically 2–10 % in creams and serums for skin-lightening (tyrosinase-inhibition), barrier repair and anti-acne effects. The cosmetic assay asks "is the active present at its declared concentration, and is it stable in the formulation":

• Content assay — HPLC/UPLC quantification of nicotinamide against the label claim (typical LOD 12.5 µg/g, LOQ 25 µg/g in formulated product), with the result expressed as % or mg/g.
• Stability — nicotinamide can hydrolyse to nicotinic acid over time, especially at low pH or high temperature; the assay tracks nicotinamide loss and nicotinic-acid formation through accelerated stability.
• Function — where a tyrosinase-inhibition (whitening) claim is made, an enzymatic or cell-based tyrosinase-activity assay supports the claim.

What Belongs on the Report?

A compliant nicotinamide test report states the service, the matrix, the standard / method, the detection limit and the result against the applicable reference — content vs label claim (food/feed/supplement/cosmetic); concentration vs reference range or deficiency cutoff (clinical); active % vs label and stability profile (cosmetic). The single most common reporting error is conflating the services — e.g. reporting a clinical blood nicotinamide number against a food mg/g limit, or quoting an NMN-supplement result for a nicotinamide product.

For related services, see our Health Food Testing for China SAMR and Cosmetics testing.

FAQ

What is the difference between nicotinamide and NMN (nicotinamide mononucleotide)?
Nicotinamide is the amide form of vitamin B3 (CAS 98-92-0), the direct NAD⁺ precursor and the substance assayed in food/supplement/clinical testing. NMN is a larger nucleotide (nicotinamide + ribose + phosphate) that is also an NAD⁺ precursor and is sold as a separate "anti-aging" supplement. They are different molecules with different methods; the much-publicised NMN-supplement-quality studies (deviations of −100 % to +28.6 %) are about NMN, not nicotinamide.

Why is a blood test unreliable for vitamin B3 status?
Because plasma niacin/nicotinamide spikes ~2 h after any intake (food or supplement) and drops again — a snapshot that does not reflect body stores. The NIH states blood levels are "not reliable indicators of niacin status". The gold standard is 24-h urinary excretion of N¹-methylnicotinamide + 2-pyridone, which reflects stores over time; blood is reserved for toxicity monitoring of high-dose therapy.

What Chinese standards apply to nicotinamide in foods and feed?
GB 5009.89-2023 (method for nicotinic acid + nicotinamide in food), GB 14753 (food-additive grade), GB 14880 (fortification use standard), GB 7301-2017 (feed-additive grade, mandatory), GB 15570 (nicotinic-acid food additive). The method is HPLC/UPLC for content; LC-MS/MS for complex/trace matrices.

What is the acceptance criterion for a nicotinamide content assay?
The measured content must match the declared/label content within the regulatory tolerance for the product class. In practice, supplement surveys show real products deviating from −100 % (no active) to +28.6 % (overage), which is exactly what a third-party content assay is commissioned to catch.

Can the same LC-MS/MS method cover food, plasma and cosmetics?
The chromatography and MS detection are broadly similar, but the sample preparation, calibration range, internal standard, detection limit and acceptance criterion differ by matrix (mg/g food vs ng/mL plasma vs % cosmetic). A method validated for one matrix is not automatically valid for another; each matrix needs its own validated method.

Our Testing Capabilities

As an ISO/IEC 17025-accredited third-party laboratory, Beijing ZKGX Research provides nicotinamide (vitamin B3) testing across the three service families:

• Food / supplement / feed content assay — nicotinamide (and nicotinic acid) by GB 5009.89-2023 (HPLC/UPLC) and LC-MS/MS in infant formula, fortified foods, dietary supplements, health foods and feed, against GB 14753 / GB 14880 / GB 7301-2017 / GB 15570 limits and label claims.
• Clinical nutritional-status testing — plasma/serum nicotinamide + nicotinic acid + nicotinuric acid by LC-MS/MS (toxicity monitoring of high-dose therapy); 24-h urinary N¹-methylnicotinamide + 2-pyridone for deficiency/status assessment, against the published reference ranges.
• Cosmetic active assay — nicotinamide content in creams/serums/lotions by HPLC/UPLC (LOD 12.5 µg/g, LOQ 25 µg/g) against label claim, with hydrolysis-to-nicotinic-acid stability and tyrosinase-inhibition functional support where claimed.

Sample types include infant formula, milk powder, fortified foods, dietary supplements, health foods, feed additives, pharmaceutical-grade nicotinamide, cosmetic formulations, and clinical plasma/urine/hair specimens. If you have a specific matrix, regulatory target (GB / NMPA / FDA / EU), or acceptance criterion (label claim tolerance / deficiency cutoff / active %), contact the laboratory to confirm the correct standard, method and reporting format before testing.